<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROXYZINE HYDROCHLORIDE - hydroxyzine hydrochloride tablet, film coated </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>HYDROXYZINE HYDROCHLORIDE
TABLETS, USP
Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>HydrOXYzine hydrochloride has the chemical name of 2-[2-[4-(p-Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride.</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0f40d4e-4167-4641-a8a4-599bc1877077&amp;name=MM1.jpg"></p>
<p> C<span class="Sub">21</span>H<span class="Sub">27</span>ClN<span class="Sub">2</span>O<span class="Sub">2</span>•2HCl                                M.W.447.83</p>
<p>HydrOXYzine hydrochloride occurs as a white, odorless powder which is very soluble in water.</p>
<p>Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydrOXYzine HCI. Inactive ingredients include: lactose monohydrate, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, stearic acid, polyethylene glycol, polysorbate 80, and titanium dioxide.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>HydrOXYzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. HydrOXYzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.</p>
<p>Primary skeletal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.</p>
<p>Pharmacological and clinical studies indicate that hydrOXYzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.</p>
<p>HydrOXYzine is rapidly absorbed from the gastrointestinal tract and hydrOXYzine's clinical effects are usually noted within 15 to 30 minutes after oral administration.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>For symptomatic relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">psychoneurosis</span> and as an adjunct in organic disease states in which <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> is manifested.</p>
<p>Useful in the management of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> due to allergic conditions such as <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span> and <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> and contact dermatoses, and in histamine-mediated <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>As a sedative when used as a premedication and following general anesthesia, <span class="Bold">hydrOXYzine may potentiate meperidine and barbiturates,</span> so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.</p>
<p>The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>HydrOXYzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydrOXYzine is contraindicated in early pregnancy.</p>
<p>HydrOXYzine is contraindicated for patients who have shown a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p><span class="Bold">Nursing Mothers</span></p>
<p>It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydrOXYzine should not be given to nursing mothers.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydrOXYzine their dosage should be reduced.</p>
<p>Since <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydrOXYzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.</p>
<p>
 
</p>
<p></p>
<p>A determination has not been made whether controlled clinical studies of hydrOXYzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>The extent of renal excretion of hydrOXYzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over sedation in the elderly; elderly patients generally should be started on low doses of hydrOXYzine and observed closely.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Side effects reported with the administration of hydrOXYzine hydrochloride are usually mild and transitory in nature.</p>
<p><span class="Bold">Anticholinergic:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>.</p>
<p><span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have been reported, usually with doses considerably higher than those recommended. Clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has not been reported at recommended doses.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>The most common manifestation of hydrOXYzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.</p>
<p>If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydrOXYzine counteracts its pressor action.</p>
<p>There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydrOXYzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydrOXYzine in body fluids or tissue after its ingestion or administration.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>For symptomatic relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">psychoneurosis</span> and as an adjunct in organic disease states in which <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> is manifested: Adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.</p>
<p>For use in the management of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> due to allergic conditions such as <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span> and <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> and contact dermatoses and in histamine-mediated <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.</p>
<p>As a sedative when used as a premedication and following general anesthesia: 50-100 mg for adults and 0.6 mg/kg of body weight in children.</p>
<p>When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.</p>
<p>As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>HydrOXYzine Hydrochloride Tablets, USP,</p>
<p>10 mg - Round, white, film-coated tablet, debossed "H/105", supplied in bottles of 100, 500, and 1000.</p>
<p>Bottles of 100                                    <span class="Bold">NDC</span> 23155-105-01<br>Bottles of 500                                    <span class="Bold">NDC</span> 23155-105-05<br>Bottles of 1000                                  <span class="Bold">NDC</span> 23155-105-10</p>
<p>25 mg - Round, white, film-coated tablet, debossed "H/106", supplied in bottles of 100, 500, and 1000.</p>
<p>Bottles of 100                                    <span class="Bold">NDC</span> 23155-106-01<br>Bottles of 500                                    <span class="Bold">NDC</span> 23155-106-05<br>Bottles of 1000                                  <span class="Bold">NDC</span> 23155-106-10</p>
<p>50 mg - Round, white, film-coated tablet, debossed "H/107", supplied in bottles of 100. 500, and 1000.</p>
<p>Bottles of 100                                    <span class="Bold">NDC</span> 23155-107-01<br>Bottles of 500                                    <span class="Bold">NDC</span> 23155-107-05<br>Bottles of 1000                                  <span class="Bold">NDC</span> 23155-107-10</p>
<p>Dispense in a tight container as defined in the USP.</p>
<p>Store at controlled room temperature 20°-25°C (68°-77°F); [see USP Controlled Room Temperature].</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>Manufactured for:<br>Heritage Pharmaceuticals Inc. <br>Edison, NJ 08837 <br>1.866.901.DRUG (3784)</p>
<p>Manufactured by: <br>ANDAPharm,LLC<br>Ft. Lauderdale, FL 33309<br>Iss. 06/09</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Hydroxyzine Hydrochloride </p>
<p><br></p>
<p>GENERIC: Hydroxyzine Hydrochloride</p>
<p><br></p>
<p>DOSAGE: TABLET, FILM COATED</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 52125-822-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>HYDROXYZINE HYDROCHLORIDE 50mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>CELLULOSE, MICROCRYSTALLINE</li>
<li>STEARIC ACID</li>
<li>POLYETHYLENE GLYCOL</li>
<li>POLYSORBATE 80</li>
<li>SODIUM STARCH GLYCOLATE TYPE A POTATO</li>
<li>HYPROMELLOSE</li>
<li>SILICON DIOXIDE</li>
<li>LACTOSE MONOHYDRATE</li>
<li>MAGNESIUM STEARATE</li>
<li>TITANIUM DIOXIDE</li>
</ul>
<p><br></p>
<p>COLOR: white</p>
<p><br></p>
<p>SHAPE: ROUND</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 9 mm</p>
<p><br></p>
<p>IMPRINT: H;107</p>
<p><br></p>
<p>PACKAGING: 30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0f40d4e-4167-4641-a8a4-599bc1877077&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0f40d4e-4167-4641-a8a4-599bc1877077&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROXYZINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">hydroxyzine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-822(NDC:23155-107)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROXYZINE HYDROCHLORIDE</strong> (HYDROXYZINE) </td>
<td class="formItem">HYDROXYZINE HYDROCHLORIDE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H;107</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-822-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040804</td>
<td class="formItem">01/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e906b1f-9624-4b8a-a1c7-c981616f5313</div>
<div>Set id: e0f40d4e-4167-4641-a8a4-599bc1877077</div>
<div>Version: 1</div>
<div>Effective Time: 20140130</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
